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The aim of the present study was to investigate the relationship ofMET copy number (CN) andMETmRNA expression
to other molecular alterations, clinicopathologic characteristics, and survival of patients with resected non–small cell
lung cancer. One hundred fifty-one paired surgical samples of tumor and tumor-distant normal lung tissues were
analyzed by comparative quantitative polymerase chain reaction (PCR) methods with commercially available assays
and the CopyCaller software v. 1.0 for post-PCR data processing (downloadable fromwww.appliedbiosystems.com).
MET copy gain (set asmore than 3.0 copies per cell) was found in 18.5%of the samples and occurredmore frequently
in the adenocarcinomas (ADCs) with an increased epidermal growth factor receptor (EGFR) or human epidermal
growth factor receptor 2 (HER2) CN (P = .001 and .030 for EGFR and HER2, respectively) and in the ADCs with
EGFR activating mutations (P = .051) but did not correlate with KRAS dosage or mutational status. MET mRNA level
was 1.76-fold higher [95% confidence interval (CI), 1.29-2.40] in the tumor compared to unaffected lung tissue and
associated significantly withMETCN (beta coefficient, 1.51; 95%CI, 1.22-1.87; P b .001). In themultivariable analysis,
patients diagnosedwith ADCwith increasedMETCNhad a significantly higher risk of disease recurrence (hazard ratio,
1.76; 95% CI, 1.20-2.57; P = .004). An increased MET CN in combination with histologic type appears to be a
prognostic factor in patients with ADC after a curative surgery.
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High mortality rate of non–small cell lung cancer (NSCLC) patients
after a curative surgery [1] suggests that the tumor-node-metastasis
(TNM) staging system is insufficient for patient’s prognosis and
therapeutic decisions and that new prognostic factors are needed [2].
Aberrations of MET proto-oncogene, frequently observed in cancer
[3,4], are one of themolecular factors with a possible prognostic potential
[5]. An association between MET copy gains and a worse prognosis in
patients with NSCLC has been found previously [6–9], but the data are
limited and inconsistent. Recently, an increase in MET copy number
(CN) has been demonstrated to be responsible for about 20% cases of
the acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in
patients with NSCLC [10,11], suggesting that, as a pre-existing
condition occurring before treatment, it may provide a primary lack of
response [12], although a number of researchers deny that possibility[10,13]. The rate ofMET copy gain in NSCLC reported thus far ranges
significantly from 3% to 21% depending on the detection technique
used [6,7,14–17] and patient cohort differences [15]. Moreover,
although a few studies examined the association between MET CN
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mRNA expression in lung cancer are available.
The aim of the present study was to evaluateMET CN and mRNA
expression level in stage I to IIIA NSCLC tumor samples and to assess
their associations with clinicopathologic characteristics of the patients
including the postoperative outcome. In addition, the relations
between the mutational status of epidermal growth factor receptor
(EGFR), human epidermal growth factor receptor 2 (HER2), and
KRAS genes and MET CN alterations were analyzed.
Materials and Methods
Study Subjects and Tissue Samples
The study was performed on pairs of freshly frozen cancerous and
unaffected lung tissue specimens obtained from patients with NSCLC
stage I to IIIA (pTNM, 7th edition, 2009) who underwent a curative
surgery at the BialystokMedical University Hospital between 2003 and
May 2010 and were followed-up for at least 3 years. None of the
patients received chemotherapy or radiotherapy before the surgery.
Tissue samples were collected intraoperatively and processed immedi-
ately after surgical resection: After the macroscopic visual assessment, the
tumors were divided into two sections. One of them was fixed in formalin
followedbyparaffin embedding and the other, aswell as the unaffected lung
tissue specimen from the same lobe or lung of the patient, was frozen in
liquid nitrogen followed by storage at −80°C. Routine hematoxylin-eosin
and immunohistochemical examination of formalin-fixed paraffin-
embedded tumor samples, including p63, cytokeratin 5/6 (CK5/6),
thyroid transcription factor 1 (TTF1), and chromogranin detection,
was performed to determine tumor histologic type. Before nucleic acid
extraction, the cryosections of frozen tissue specimens were stained with
hematoxylin-eosin and evaluated for tumor cell content. Only the
tumor samples that contained at least 50% of tumor cells on a
microscopic section were used for further processing. Consequently,
151 pairs of cancerous and matched unaffected lung tissues were
selected for the study.
Clinicopathologic data and previously detected EGFR, KRAS, and
HER2 gene mutational status were available for all the patients. For
survival analysis, the overall survival (OS) was estimated as the time from
the date of the surgery to the date of death due to lung cancer recurrence
or metastases (event) or to the date of the last control visit (censoring).
The disease-free survival (DFS) was defined as the time from the date of
the surgery to the date of disease relapse or death, whichever occurred
first (events), or to the date of the last visit (censoring).
The study was approved by the Ethics Committee of the University,
and written informed consent for specimen collection was obtained from
each patient before the surgery.
Nucleic Acid Extraction
DNA and RNA were isolated simultaneously using a magnetic
extraction method. Briefly, about 40 to 50 mg of tissue was disrupted
in lysis buffer (Biomerieux, Marcy l'Etoile, France) with TissueRupter
(Qiagen,Hilden,Germany) and incubatedwith Proteinase K for 2 hours
at 56°C. Nucleic acids from deproteinated cell lysates were extracted
automatically on the EasyMag machine (bioMérieux) according to the
producer’s protocol. Both DNA and RNA were present in the 100-μl
resulting extracts. Nucleic acid quality was assessed electrophoretically.
For gene expression analysis, RNA was transcripted into
cDNA in a reaction with High Capacity RNA-to-cDNA Master
Mix (Applied Biosystems, Foster City, CA) according to the
producer’s recommendations.MET CN
MET CN was analyzed by a quantitative real-time duplex
polymerase chain reaction (qPCR) on an ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems) with a commer-
cially available predesigned MET TaqMan Copy Number Assay
(Hs0143282_cn) and a Reference RNase P Assay (PN4412907),
both from Applied Biosystems. The qPCR was done in a 20-μl
reaction mixture containing 10 μl of Applied Biosystems TaqMan
Universal PCR Master Mix with UNG, 1 μl of the CN assay
solution, 1 μl of the reference assay solution, and 5 μl of DNA
solution according to the following cyclic conditions: 50°C for
2 minutes followed by holding for 10 minutes at 95°C and 40 cycles
of 95°C for 15 seconds and 60°C for 60 seconds. Each sample was
analyzed in quadruplicate. The raw post-PCR data were used for
MET CN calculation by the relative quantification method using
the CopyCaller v.1.0 software (PN4412907) downloadable from
www.appliedbiosystems.com. MET copy gain was defined as more
than three copies per cell.
MET mRNA Expression
METmRNA expression level in the tumor and unaffected lung tissues
was evaluated with the comparative real-time reverse transcription–PCR
method. Ribosomal 18S RNA (18SrRNA) gene with a relatively low level
of the expression variability in lung tissue [19,20] was used to normalize
for the differences in the input cDNA concentration. The amplification
was performed in a 20-μl mixture containing 10 μl of TaqMan
Universal PCR Master Mix with UNG, 1 μl of the MET
(Hs01565584_m1) or 18S rRNA (Hs99999901_s1) TaqMan Gene
Expression Assay (all reagents from Applied Biosystems), and 5 μl of
cDNA solution. Each sample was analyzed in triplicate on an ABI
PRISM 7900HT Sequence Detection System equipped with the SDS
v.2.4 software for baseline and Ct calculations. MET expression was
inversely proportional to the difference between Ct for MET and Ct
for 18S rRNA gene (ΔCt = CtMET −Ct18S rRNA). Fold changes (FCs)
in MET expression between the tumor and paired normal lung tissues
from the same patient were calculated as FC = 2 − ΔΔCt, where
ΔΔCt equaled MET expression in tumor (ΔCtT) calibrated by its
expression in the corresponding nonmalignant tissue (ΔCtN) as
follows: ΔΔCt = ΔCtT − ΔCtN.
EGFR, HER2, and KRAS Alterations
EGFR and KRAS activating mutations were detected with direct
sequencing of the PCR-amplified EGFR exons 19 and 21 and KRAS
2 exons. EGFR, HER2, and KRAS CNs were analyzed like MET
CN with the corresponding TaqMan Copy Number Assays from
Applied Biosystems (Hs014326560_cn, Hs00159103_cn, and
Hs02802859_cn for EGFR, HER2, and KRAS, respectively).
Gene copy gain was defined as more than three copies per cell.
Statistical Analysis
The nonparametric Mann-Whitney test, Kruskal-Wallis test, or
Pearson chi-squared test was used to analyze the associations between
clinicopathologic characteristics and MET CN. The differences in
MET expression between the tumor and unaffected lung tissues
were analyzed with paired t test. The linear regression model was
used to estimate the relation between MET CN and the expression
level. The associations between MET gene copy number (CNG) and
EGFR, HER2, and KRAS gene status were analyzed with Pearson
chi-squared test. OS and DFS were calculated and plotted with
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between the groups. Cox proportional hazard model was used to
evaluate the effect of clinicopathologic and molecular variables on OS
and DFS. P values less than .05 were considered as significant. All the
statistical analyses in this study were performed using STATA/SE
11.1 software.
Results
Patient Characteristics
A total of 151 patients with NSCLC aged from 39 to 82 years
(median age, 63.0 years) was included in the study. The majority of
the patients were males (78.8%) and current or former smokers
(90.7%). According to the TNM classification, pathologic staging
were given as follows: stage I in 58 (38.4%) patients, stage II in
62 (47.0%) patients, and stage IIIA in 22 (14.6%) patients. About
40% of the patients had mediastinal lymph node metastases at the
time of surgery, classified as stage N1 and stage N2 in 43 (28.5%) and
18 (11.9%) patients, respectively. The study comprised 64 cases of
adenocarcinoma (ADC), 35 cases of large cell carcinoma (LCC), and
52 cases of squamous cell carcinoma (SCC) of the lung (Table 1).
MET CN
ThemedianMETCN in tumor tissue was 2.05 (ranged from 0.50 to
7.40) and was not significantly affected by analyzed clinicopathologic
variables. With 3.0 copies used as a cutoff inMETCN evaluation, gene
copy gain was observed in 28 (18.5%) tumor samples, including 15Table 1. Relationship between MET CN, MET mRNA Level, and Patients’ Clinicopathologic Chara
Variable CalculatedMET CN in
Tumor Tissue
Patient Number with Calculated
MET CN
n (%) Median P Value b3.0 ≥3.0 P Va
n (%) n (%)
Total 151 2.05 123 (81.5) 28 (18.5)
Age (years)
b63 75 2.09 59 (78.7) 16 (21.3)
≥63 76 1.98 .208 ‡ 64 (84.2) 12 (15.8) .381
Gender
Female 32 (21.2) 2.04 27 (84.4) 5 (15.6)
Male 119 (78.8) 2.05 .859 ‡ 96 (80.7) 23 (19.3) .632
Smoking
Never 14 (9.3) 2.08 12 (85.7) 2 (14.3)
Ever 137 (90.7) 2.04 .974 ‡ 111 (81.0) 26 (19.0) .667
Histology
ADC 64 (42.4) 1.98 51 (79.7) 13 (20.3)
LCC 35 (23.2) 2.05 27 (77.1) 8 (22.9)
SCC 52 (34.4) 1.94 .779 # 45 (86.5 7 (13.5) .484
pTNM
I 58 (38.4) 2.04 48 (84.5) 9 (15.5)
II 71 (47.0) 2.05 58 (81.7) 13 (18.3)
IIIA 22 (14.6) 1.94 .759 # 26 (81.2) 6 (18.8) .894
Lymph node metastases
No 90 (59.6) 2.05 74 (82.2) 16 (17.8)
N1 to N2 61 (40.4) 2.04 .462 ‡ 49 (80.3) 12 (19.7) .769
Lymph node pathologic status
N0 90 (59.6) 2.05 74 (82.2) 16 (17.8)
N1 43 (28.5) 2.04 36 (83.7) 7 (16.3)
N2 18 (11.9) 1.94 .759 # 13 (72.2) 5 (27.8) .550
* Geometric mean.
† 95% CI for geometric mean.
‡ Wilcoxon rank-sum test.
§ Pearson chi-squared test.
¶ Two-sample t test with Welch’s correction for unequal variances.
# Kruskal-Wallis rank test.
** One-way analysis of variance test with Bonferroni multiple comparison.cases with 3.0 to 3.99 MET copies per cell and the remaining 13
samples containing from 4.0 to 7.7 copies (Table 1).
In our cohort of patients with NSCLC, MET CNG was
observed approximately 2.7- and 2.0-fold more frequently in the
tumors with increased EGFR and HER2 CN compared to the
tumors without the increase (P = .002 and .049 for EGRF and
HER2, respectively) and about 2.4-fold more frequently in tumors
harboring EGFR mutations compared to tumors with wild-type
EGFR (P = .071). However, subgroup analysis for particular
tumor histologic types revealed that statistically significant
associations between MET CNG and EGFR or HER2 gene
alterations occurred only in the ADC group but not in the LCC or
SCC group. No associations between MET CN and KRAS gene
mutations or copy gain were found in particular histologic types of
cancer (Table 2).
MET mRNA Expression
We were unable to determine MET cDNA in 16 analyzed tumor
and/or normal lung tissue specimens and these paired samples were
excluded from the assay. The MET mRNA level was significantly
higher in tumor tissue as compared to unaffected tissue (relative
quantity (RQ) geometric mean, 1.76; 95% confidence interval (CI),
1.29-2.40; P b .001). However, with respect to tumor histologic types,
a statistically significant alteration was obtained only in ADCs (RQ
geometric mean, 2.14; 95% CI, 1.33-3.45; P b .001). No significant
associations betweenMETmRNA expression and patients’ characteristics
were found (Table 1).cteristics
MET mRNA Level in Tumor
Tissue (ΔCt Value)
Differences inMET mRNA Levels between Tumor and
Unaffected Lung Tissues
lue n Mean ± SD P Value Log2(FC) FC
n Mean ± SD P Value Mean * 95% CI †
142 15.63 ± 2.26 135 0.82 ± 2.63 1.76 1.29-2.40
71 15.60 ± 2.12 67 0.95 ± 2.33 1.93 1.30-2.86
§ 71 15.67 ± 2.41 .858 ¶ 68 0.69 ± 2.92 .567 ¶ 1.61 0.99-2.63
30 15.11 ± 2.32 30 0.81 ± 2.93 1.75 0.82-3.73
§ 112 15.77 ± 2.23 .142 ¶ 105 0.82 ± 2.56 .979 ¶ 1.77 1.25-2.49
13 15.23 ± 2.70 12 0.45 ± 3.81 1.36 0.26-7.30
§ 129 15.67 ± 2.22 .466 ¶ 123 0.85 ± 2.51 .725 ¶ 1.81 1.32-2.46
60 15.38 ± 2.15 59 1.10 ± 2.62 2.14 1.33-3.45
33 16.24 ± 2.59 32 0.47 ± 2.36 1.39 0.77-2.51
§ 49 15.54 ± 2.13 .205 ** 44 0.69 ± 2.84 .516 ** 1.61 0.88-2.93
57 15.64 ± 2.50 54 0.95 ± 2.31 1.93 1.25-3.00
66 15.61 ± 2.23 62 0.66 ± 3.03 1.91 0.93-2.70
§ 22 15.69 ± 1.65 .989 ** 19 0.93 ± 2.14 .824 ** 1.91 0.93-3.91
85 15.81 ± 2.35 81 0.77 ± 2.72 1.70 1.12-2.58
§ 57 15.38 ± 2.12 .267 ¶ 54 0.89 ± 2.52 .790 ¶ 1.85 1.15-2.99
85 81 0.77 ± 2.72 1.70 1.12-2.58
41 38 0.75 ± 2.68 1.68 0.91-3.10
§ 16 .527 ** 16 1.22 ± 2.12 .808 ** 2.33 1.07-5.11
Table 2. Associations between MET CN and EGFR, HER2, and KRAS Gene Status (Pearson Chi-Squared Test)
Gene Status All Patients Patients with ADC Patients with LCC Patients with SCC
Total MET CN Total MET CN Total MET CN Total MET CN
b3.0 ≥3.0 P Value b3.0 ≥3.0 P Value b3.0 ≥3.0 P Value b3.0 ≥3.0 P Value
N (%) n (%) n (%) N (%) n (%) n (%) N (%) n (%) n (%) N (%) n (%) n (%)
EGFR CN
b3.0 119 (78.8) 103 (86.6) 16 (13.4) 48 (75.0) 43 (89.6) 5 (10.4) 24 (68.6) 20 (83.3) 4 (16.7) 47 (90.4) 40 (85.1) 7 (14.9)
≥3.0 32 (21.2) 20 (62.5) 12 (37.5) .002 16 (25.0) 8 (50.0) 8 (50.0) .001 11 (31.4) 7 (63.6) 4 (36.4) .198 5 (9.6) 5 (100.0) 0 (0.0) .354
EGFR mutations
No 141 (93.4) 117 (83.0) 24 (17.0) 55 (85.9) 46 (83.4) 9 (16.6) 34 (97.1) 26 (76.5) 8 (23.5) 52 (100.0) 45 (86.5) 7 (13.6)
Yes 10 (6.6) 6 (60.0) 4 (40.0) .071 9 (14.1) 5 (55.6) 4 (44.4) .052 1 (2.9) 1 (100.0) 0 (0.0) .581 0 (0.0) 0 (0.0) 0 (0.0)
EGFR alterations (copy gain and/or mutation)
No 113 (74.8) 97 (85.8) 16 (14.2) 43 (67.2) 38 (88.4) 5 (11.6) 23 (65.7) 19 (82.6) 4 (17.4) 47 (90.4) 40 (85.1) 7 (14.9)
Yes 38 (21.8) 26 (68.4) 12 (31.6) .017 21 (32.8) 13 (61.9) 8 (38.1) .013 12 (34.3) 8 (66.7) 4 (33.3) .286 5 (9.6) 5 (100.0) 0 (0.0) .354
HER2 CN
b3.0 118 (78.2) 100 (84.7) 23 (15.3) 49 (76.6) 42 (85.7) 7 (14.3) 26 (74.3) 21 (80.8) 5 (19.2) 43 (82.7) 37 (86.1) 6 (13.9)
≥3.0 33 (21.8) 18 (69.7) 10 (30.3) .049 15 (23.4) 9 (60.0) 6 (40.0) .030 9 (25.7) 6 (66.7) 3 (33.3) .385 9 (17.3) 8 (88.9) 1 (11.1) .820
KRAS CN
b3.0 106 (70.7) 87 (82.1) 19 (17.9) 47 (74.6) 37 (78.7) 10 (21.3) 25 (71.4) 19 (76.0) 6 (24.0) 34 (65.4) 31 (91.2) 3 (8.8)
≥3.0 44 (29.3) 35 (79.6) 9 (20.4) .717 16 (25.4|) 13 (81.4) 3 (18.7) .829 10 (28.6) 8 (80.0) 2 (20.0) .799 18 (34.6) 14 (77.8) 4 (22.2) .178
KRAS mutations
No 136 (90.1) 109 (80.2) 27 (19.8) 51 (79.7) 39 (76.5) 12 (23.5) 33 (94.3) 25 (75.8) 8 (24.4) 52 (100.0) 45 (86.5) 7 (13.5)
Yes 15 (9.9) 14 (93.3) 1 (6.7) .212 13 (20.30 12 (92.3) 1 (7.7) .205 2 (5.7) 2 (100.0) 0 (0.0) .428 0 (0.0)
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mRNA Expression
Linear regression model revealed a statistically significant link
between MET CN and mRNA expression in lung tumor tissue
(Figure 1). Gain of an additional gene copy resulted in 1.51-fold
increase in the expression level (95% CI, 1.22-1.87; P b .001).
Patient Survival
During the follow-up period, 34.4% of the patients showed disease
recurrence and most of them (31.8%) died. The median OS was
30 months (ranged from 2 to 86 months), and the DFS was
33 months (ranged from 2 to 85 months). In Kaplan-Meier curve
analysis, neither MET CN alterations nor MET mRNA expression
level influenced patients’ OS or DFS (Figure 2, A and B). However,
when the analysis was restricted to patients with ADC histology, bothFigure 1. Association between MET CN and MET mRNA
expression in lung tumor tissue of the 135 patients with NSCLC
(with a model of linear regression).DFS and OS were shorter in the cases with an increased MET CN,
although only DFS difference was statistically significant (log-rank
test, P = .044 and P = .071 for DFS and OS, respectively; Figure 2, C
and D). In contrast, in patients with SCC, MET copy gain was
associated with a better outcome in terms of both DFS and OS in
Kaplan-Meier analysis (log-rank test, P = .03 and P = .05 for DFS and
OS, respectively; Figure 2, E and F). In patients with LCC, no effect
of MET CNG on DFS or OS was found (data not shown).
For the whole cohort of the patients, in both univariate and
multivariate proportional hazards models including patients’ age,
gender, smoking habit, TNM stage of the disease (I vs II + IIIA),
lymph node metastases, MET CN, MET mRNA level in tumor, and
tumor-associated alteration in MET mRNA, only the disease stage
was an independent prognostic factor in terms of OS and DFS
[hazard ratio (HR), 12.95 and 2.66; 95% CI, 4.36-38.46 and 1.13-
6.23; P b .001 and P = .024 for OS and DFS, respectively; Table 3].
However, in the univariate model, patients with ADC harboring
increasedMET CN had a 1.58-fold higher risk of disease relapse than
those without a CNG (HR, 1.58; 95% CI, 1.10-2.27; P = .013). The
significance also remained in the simplified multivariate model after
age, TNM stage, lymph node metastases, MET mRNA level in
tumor, and tumor-associated alteration in MET mRNA removal
(HR, 1.76; 95% CI, 1.20-2.57; P = .004; Table 4). No effect of
analyzed parameters on DFS or OS in patients with LCC or SCC was
found (Tables 4 and 5).
Discussion
In the current study, we showed a gain in MET CN in 18.5% of the
analyzed tumors and a 1.76-fold tumor-associated increase in MET
mRNA expression level. The observed proportion of MET copy gain
was about two-fold higher than those in most previously reported
studies, possibly due to different methods and scoring criteria used.
In most investigations, the fluorescence in situ hybridization (FISH)
or a similar (like silver or bright-field in situ hybridization) method
was used and about 10% of NSCLCs were defined as MET FISH-
Figure 2. Kaplan-Meier survival curves of OS and DFS for the 151 patients with NSCLC in relation to MET CN (solid line in the case of
MET CN b 3.0; dashed line in the case ofMET CN≥ 3.0) in lung tumor tissue: (a and b) for the overall NSCLC patient group, (c and d) for the
ADC patients only, and (e and f) for the SCC patients only.
Table 3. Univariate and Multivariate Analyses of Prognostic Factors for DFS and OS of Patients with NSCLC (Cox Proportional Hazards Model)
Variable DFS OS
Univariate Multivariate Univariate Multivariate
HR 95% CI * P Value HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value
Age 1.00 0.97-1.04 .999 0.99 0.95-1.02 .458 1.01 0.98-1.05 .536 0.98 0.99-1.02 .258
Gender (female/male) 0.82 0.43-1.57 .549 0.67 0.32-1.43 .303 1.35 0.63-2.88 .444 1.12 0.44-2.83 .817
Smoking (never/ever) 2.15 0.67-6.91 .199 1.96 0.50-7.74 .335 2.15 0.67-6.91 .199 1.02 0.25-4.18 .983
pTNM (I/II + IIIA) 2.41 1.30-4.46 .005 2.66 1.13-6.23 .024 9.24 3.58-23.82 b .001 12.95 4.36-38.46 b .001
Lymph node metastases (no/yes) 1.55 0.90-2.68 .115 1.14 0.53-2.43 .745 1.93 1.08-3.44 .027 0.75 0.36-1.56 .445
MET CN calculated 1.13 0.91-1.41 .279 1.21 0.92-1.59 .175 1.06 0.83-1.37 .625 1.03 0.76-1.40 .849
MET mRNA in tumor (ΔCt value) 0.98 0.88-1.10 .749 1.04 0.86-1.27 .687 0.97 0.87-1.12 .832 0.96 0.78-1.19 .731
Log2(MET mRNA RQ) 1.01 0.91-1.13 .845 1.10 0.92-1.32 .309 1.04 0.92-1.17 .546 1.12 0.92-1.36 .260
MET mRNA RQ 1.00 0.99-1.01 .481 0.99 0.98-1.00 .204 1.00 0.99-1.01 .651 0.99 0.98-1.01 .330
* 95% CI for HR.
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Table 4. Multivariate Analysis of Prognostic Factors for DFS by Histologic Type (Cox Proportional Hazards Model)
Variable ADC SCC LCC
HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value
Age 0.97 0.92-1.02 .197 1.00 0.93-1.06 .898 1.08 0.96-1.22 .214
Gender (female/male) 0.24 0.06-0.89 .033 0.56 0.14-2.20 .407 0.24 0.03-2.14 .202
Smoking (never/ever) * 40.97 2.04-823.49 .015 0.59 0.09-3.75 .578
pTNM (I/II + IIIA) 3.64 0.68-19.48 .131 1.97 0.46-8.48 .361 11.63 1.13-119.33 .039
Lymph node metastases (no/yes) 0.65 0.13-3.15 .592 0.70 0.23-2.17 .540 2.42 0.45-12.88 .301
MET CN calculated 1.46 0.91-2.37 .118 0.58 0.29-1.19 .136 1.44 0.80-2.61 .225
MET mRNA in tumor (ΔCt value) 0.76 0.49-1.18 .218 1.17 0.87-1.58 .300 0.68 0.35-1.32 .255
Log2(MET mRNA RQ) 0.88 0.59-1.31 .529 1.08 0.85-1.36 .538 0.83 0.44-1.57 .569
MET CN calculated † 1.76 1.20-2.57 .004
Gender (female/male) † 0.29 0.09-0.94 .038
Smoking (never/ever) † 19.62 2.03-189.77 .010
MET CN calculated ‡ 1.33 0.86-2.06 .199
pTNM (I/II + IIIA) ‡ 5.77 1.46-22.90 .013
MET CN calculated § 1.58 1.10-2.27 .013 0.60 0.35-1.04 .068 1.42 0.91-2.21 .118
* There were no nonsmokers among patients with SCC included in the study.
† Simplified analysis after age, pTNM, lymph node metastases, MET mRNA level in tumor, and log2(MET mRNA FC) removal from the model at the last step of the multivariable analysis.
‡ Simplified analysis after age, gender, smoking, lymph node metastases, MET mRNA level in tumor, and log2(MET mRNA FC) removal from the model at the last step of the multivariable analysis.
§ Univariate analysis.
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the cutoff criteria applied [8,9]. Very recently, Jin et al. found MET
gene CNG by silver in situ hybridization in 24.1% of Korean
NSCLC patients, although only stage I ADCs had been included in
the study [17]. In our study, we used a qPCR method with a
commercially available assay forMET CN evaluation and defined the
cutoff value for copy gain as 3.0. Our results are similar to those
obtained by Beau-Faller et al. [21] who also applied the qPCR
technique. However, when we followed the cutoff definition by
Beau-Faller as a mean CN in the corresponding normal lung tissues
plus two SDs (equal to 3.99; data not shown), only 8.6% of the
tumor samples analyzed in our study demonstrated an increased gene
dosage, similar to the data reported by others [16,22].
According to our study,MET dosage status was not associated with
the analyzed clinicopathologic features like age, gender, smoking
history, histology, or pathologic stage. These results are in line with
most previously reported data [8,15,16], although in a number of
studies an increased MET CN was found to be more common in
ADCs [18], women [7], smokers [7,17,22], and in larger [17] and
poorly differentiated tumors [6,18]. A higher prevalence of MET
amplification was also shown in advanced (pTNM III-IV) NSCLCsTable 5. Multivariate Analysis of Prognostic Factors for OS by Histologic Type (Cox Proportional H
ADC (N = 64) SC
HR 95% CI P Value HR
Age 0.96 0.92-1.00 .116 0.9
Gender (female/male) 1.04 0.21-5.24 .965 0.6
Smoking (never/ever) * 3.30 0.12-87.46 .475
pTNM (I/II + IIIA) 12.37 1.95-78.50 .008 9.3
Lymph node metastases (no/yes) 0.63 0.13-3.07 .567 0.5
MET CN calculated 1.00 0.57-1.75 .993 0.6
MET mRNA in tumor (ΔCt value) 0.80 0.50-1.29 .363 1.2
Log2(MET mRNA RQ) 1.08 0.71-1.64 .708 1.1
MET CN calculated † 1.17 0.79-1.74 .429 0.6
pTNM (I/II + IIIA) † 6.44 1.81-22.99 .004 8.3
MET CN calculated ‡
Gender (female/male) ‡
pTNM (I/II + IIIA) ‡
MET CN calculated § 1.39 0.92-2.11 .121 0.6
* There were no nonsmokers among patients with SCC included in the study.
† Simplified analysis after age, gender, smoking, lymph node metastases, MET mRNA level in tumor, and
‡ Simplified analysis after age, smoking, lymph node metastases, MET mRNA level in tumor, and log2(ME
§ Univariate analysis.compared to early-stage (pTNM I-II) cases [6,9,22] and in stage IA
ADCs compared to stage IB ones [17], as well as in lymph node stage
2 metastases compared to primary tumors [23].
We also found a statistically significant association between MET
copy gain and an increase in MET mRNA level in tumor tissue. The
association between MET dosage status and the expression at protein
level by immunohistochemistry has been explored in a number of
studies and a strong correlation has invariably been shown [7,16,17].
However, to our best knowledge, the present study is the first
investigation where this association was demonstrated at mRNA level,
suggesting that MET overexpression in the cells with an increased
gene CN at least partly results from an enhanced transcription level.
According to the present study, the rate ofMET copy gain was found
to be higher in the tumors harboring increased EGFR or HER2 CN
and/or EGFR activating mutations as compared to the tumors without
these alterations. However, these associations were statistically
significant only in ADC cases (with the exception of the association
with EGFRmutations that did not reach the statistical significance) but
not in LCC or SCC tumors. However, no correlation between MET
copy gain and KRAS dosage or mutational status was found. The
association betweenEGFR andMET copy gains had been demonstratedazards Model)
C (N = 52) LCC (N = 35)
95% CI P Value HR 95% CI P Value
9 0.92-1.07 .775 1.14 0.94-1.38 .192
1 0.11-3.31 .565 0.04 0.01-0.68 .026
0.17 0.01-2.57 .201
5 1.03-84.78 .047 605.46 10.50-34901.09 .002
0 0.16-1.57 .238 0.21 0.02-2.69 .235
6 0.30-1.44 .293 1.99 0.84-4.70 .116
4 0.88-1.74 .214 0.40 0.11-1.41 .155
3 0.88-1.46 .325 0.69 0.22-2.26 .550
5 0.35-1.20 .169
7 1.05-66.98 .045
1.52 0.97-2.39 .069
0.16 0.03-0.86 .032
38.67 45.04-370.22 .002
3 0.35-1.12 .117 1.20 0.79-1.82 .393
log2(MET mRNA FC) removal from the model at the last step of the multivariable analysis.
T mRNA FC) removal from the model at the last step of the multivariable analysis.
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aneuploidy in cancer cells [6]. However, a concept of the functional
cross talk between MET and EGFR family receptors in cancer cells has
also be suggested [10,24,25].
The reported relations between increased MET CN and EGFR
mutations are controversial. The alterations were found to be
mutually exclusive in some studies [25,26], yet they coexisted but not
correlated in others [7,17,21,22]. In the recent study of Jin et al., no
association between MET CNG and three most common genetic
alterations (EGFR and KRAS activating mutations and ALK
rearrangements) in lung ADCs was found. Only stage I Korean
patients had been included into the study resulting in much higher
proportion of nonsmokers and women in the patients’ cohort and
higher incidence of EGFR mutations compared to our study [17].
The relations between MET and EGFR alterations are of a great
clinical importance in the light of the hypothesis that increased MET
dosage might lead to the primary resistance of NSCLCs with EGFR
mutations to EGFR TKIs [12], as has been demonstrated for the
acquired resistance in approximately 20% of patients with NSCLC
[10,11]. Recent investigations on cell cultures and clinical studies
revealed that only a high level ofMET amplification developed under
EGFR TKI treatment and very rarely found in untreated tumors
could result in TKI resistance [10,13,27], rather contradicting the
impact of MET gene dosage on the primary response [15]. Only a
moderate increase inMET CN was found in our study. However, the
mean gene CN value for all the cells of the sample is defined by
qPCR, not excluding a high level of gene amplification in a subset of
cells due to tumor heterogeneity, as has been recently demonstrated
for KRAS [28]. A more detailed analysis of tumor samples with MET
alterations established with FISH method should clarify the issue.
Another important aspect concerning MET status is its possible
significance as a prognostic factor in NSCLC. Most of the studies
reported thus far consistently indicated a negative impact of MET
abnormalities on the survival of patients with NSCLC [6,8,17,22],
although contradictory results have also been reported [16].
According to the present study, ADC patients with an increased
MET CN had a significantly shorter DFS, and the effect was
independent of other clinicopathologic variables in the multivariate
analysis. Similar results had been obtained in a number of previous
investigations where different methods for MET gene dosage
evaluation were used [9,17,18,21]. To our surprise and in contrast
to Beau-Faller results [21], an increased MET CN correlated
significantly with a better outcome of our SCC patients in terms of
both DFS and OS but was not an independent prognostic factor in
the multivariate analysis. The prognostic impact ofMET FISH status
in patients with SCC had been reported previously by Go et al. [8],
although in their study FISH positivity was associated with a poor
survival of the patients. In the light of the current state of knowledge
on the role of hepatocyte growth factor (HGF)/MET signaling in cell
invasive growth and tumor progression, we are not able to explain the
beneficial influence of an increased MET CN on SCC patients’
outcome. Interestingly, the elevated MET CN correlated positively
with a better prognosis in patients with NSCLC in the retrospective
analysis by Kanteti et al. [29]. Further investigations on a larger
patient cohort are needed to validate these observations.
We also demonstrated a lack of correlation between MET mRNA
expression and the clinical outcome in the whole patient cohort as well
as, respectively, to a particular histologic type of tumor. Contradictory
results have been reported by others, although the prognosticimplications of MET protein expression by immunohistochemistry
(ICH) instead of gene transcription level have been examined [6,9,29].
However, no association between MET protein expression level and
survival was found in Dziadziuszko investigation, which was performed
on a similar cohort of Polish NSCLC patients [16].
Conclusion
In conclusion, the obtained results demonstrate an increase in MET
CN in a subset of untreated stage I to IIIA NSCLCs that occurs more
frequently in tumors with EGFR and/or HER2 copy gain and EGFR
activating mutations. An association between MET CN and MET
mRNA expression level in tumor tissue also exists. An increasedMET
CN determined by qPCR with a commercially available assay might
be a prognostic factor in patients with ADC after a curative surgery.
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